“We can combine existing credible research, with the data we isolate in saliva, like amino acids and various biomarkers, that when combined with even simple surveys, can point to early risks indicators of concerning diseases where early intervention a gamechanger,” says eNano CEO, Winnie Leung.
ALTOONA, Pa. (PRWEB)
April 13, 2021
COVID-19 has created an abundance of unexpected opportunities for healthcare technology companies. eNano Health Limited is jumping in with both feet to manage outbreaks and identify future indicators of viral loads.
eNano has a long history in the healthcare technology industry, starting with providing electronic medical records to US-based physicians and wellness providers. During this time, Chief Scientist Patrick Leung recognized how combining data points identifies future health concerns that patients can mitigate through awareness with lifestyle changes, often years in advance of a diagnosis. Mr. Leung then focused on identifying other data points that could enhance their program and settled on saliva as a critical focus. eNano uses their Hong Kong research lab to isolate these data points in saliva and create new tests centered on specific risks and what lifestyle changes may prevent future issues.
Winnie Leung, President, and CEO states, “We can combine existing credible research, with the data we isolate in saliva, like amino acids and various biomarkers, that when combined with even simple surveys, can point to early risks indicators of concerning diseases like cancer, diabetes, stroke, and cardiovascular diseases where early intervention via healthy lifestyle changes and treatment is a gamechanger. This idea is exciting, and we have moved forward seeking potential US-based partners.”
COVID – 19 has escalated some of their research because, as with any disease or foreign intruder in our bodies, saliva shows the body’s response to viruses. We can use saliva in multiple ways to assist in pandemic control. eNano has two key areas of research currently developing. They are,
1.) Finding early indicators of the immune system’s activation in response to viral infection to suggest temporary self-quarantine to protect their family, co-workers, and community and deploy wellness regimes – like specific foods or supplements. eNano’s saliva test can isolate data (in a particular number range) that shows something like a virus is active in our system. This allows for detection, early isolation, and early self-care.
2). Showing efficacy rates of current vaccines. Just like with the virus itself, every person responds differently. A saliva test can show the immune system’s response to vaccination. This knowledge allows organizations, governments, and individuals to move forward with confidence knowing they are safe as evidenced by the positive confirmation from the post-vaccine test.
eNano is currently invested in pilot programs in Hong Kong and the United States. John Seely, Executive Director of The Empowering Lives Foundation in Western Pennsylvania and Cleveland, Ohio (later this year), is actively engaged in a pilot program with eNano. He shares his enthusiasm, “This could be invaluable for us. While we have only recently begun our pilot program, we are already discovering evidence of vaccine efficacy and other wellness indicators leading to refining programs for the people we support. The more we know about the at-risk population we serve, the better we can create wellness through nutritional support and lifestyle changes to support them in living healthy, independent everyday lives. Many of them have an incomplete medical history; this tool gives us better insights at a low cost. Coupled with detecting a virus early, we can reduce the risk of spread or greater complications, possibly reducing healthcare costs. We are excited to see where this leads.”
To connect with eNano, contact Angie Yasulitis:
The YaZo Group
angiey@yazogroup.com
To connect with The Empowering Lives Foundation, contact John Seely:
john@empoweringlivesfound.org
814-232-1730
Share article on social media or email: